NCT05921929 is a Phase 1 clinical trial of Fluoroethylnormemantine (FENM) in PTSD, sponsored by ReST Therapeutics.

Who is sponsoring NCT05921929?

NCT05921929 is sponsored by ReST Therapeutics.

What drugs are being tested in NCT05921929?

Interventions in NCT05921929: Fluoroethylnormemantine (FENM).

What condition does NCT05921929 study?

NCT05921929 studies PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease, Major Depressive Disorder, Treatment Resistant Depression.

Is NCT05921929 still recruiting?

NCT05921929 is currently withdrawn. Last updated 3 May 2024.

Last reviewed 2024-05-03 · How we verify

NCT05921929

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

Withdrawn Phase 1 Last updated 3 May 2024

What this trial tests

Phase 1 trial testing Fluoroethylnormemantine (FENM) in PTSD. Withdrawn.

Timeline

2 May 2024

Primary endpoint
2 May 2024

2 May 2024

Quick facts

Lead sponsor	ReST Therapeutics
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Start date	2 May 2024
Primary completion	2 May 2024
Estimated completion	2 May 2024
Sites	1 location across Belgium

Drugs / interventions tested

Fluoroethylnormemantine (FENM) — full drug profile →

Conditions studied

PTSD — all drugs for PTSD →
Alzheimer Disease — all drugs for Alzheimer Disease →
Brain Diseases — all drugs for Brain Diseases →
Neuro-Degenerative Disease — all drugs for Neuro-Degenerative Disease →

Sponsor

ReST Therapeutics — full company profile →

Who can join

Adults 18 to 45, male only, with PTSD or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: * What is the safety of single ascending doses of the FluoroEthylNorMemantine (FENM)? * What is the PK profile of single ascending doses of the FENM in human? * What is the preliminary exploratory time course of Brain Disease Neurotrophic Factor (BDNF) plasmatic levels of single ascending doses of the FENM? Participants will receive one single oral dose of FENM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for PTSD

Currently open trials in the same condition.

NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
NCT07010757 — Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial · NA · recruiting
NCT07372586 — Behavioral Health Collaborative Care Model in an ICU Recovery Clinic · NA · recruiting
NCT07390786 — Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot · NA · recruiting
NCT07469098 — Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05921929 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ReST Therapeutics
Last refreshed: 3 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing